UNSPSC 51314331: Carbinoxamine/dextromethorphan/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314331 Carbinoxamine/dextromethorphan/pseudoephedrine is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities solicited naloxone and drug deactivation systems (Seminole County, Florida), therapeutic pharmacy initiative direct-to-manufacturer prescriptions (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a multistate cooperative (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target the specific cough-and-cold combination medication that the code nominally describes. The code shows little relevant recent activity; state and local procurement bodies appear to be using this code designation inconsistently with the actual pharmaceutical products and services being procured.

The Seminole County IFB (IFB60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. The Texas HHS Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products to be supplied through three authorized wholesalers with contracts effective July 1, 2026. The issuing bodies span county health departments, state health agencies, and multistate cooperative purchasing vehicles; geographic activity centers on Florida, Texas, and Minnesota with multistate reach through MMCAP. Business development professionals evaluating this code should verify the intended UNSPSC assignment before investing pursuit resources, as the recent opportunities reflect broader pharmaceutical procurement rather than the specific product class named by the code.